Overview
- Amnesty International reports the national suspension of purchasing and distributing misoprostol and mifepristone, leaving public hospitals without essential medication for legal procedures.
- The organization logged more than 400 cases in 2025 describing barriers to care, a total that it says vastly exceeds the complaints it received in 2024.
- Monitors cite an estimated 81% drop from 2023 to 2024 in the distribution of contraceptives, emergency contraception and pregnancy tests to provinces.
- An ELA/ACIJ analysis finds the national sexual‑health program executed about 20% of its 2023 budget and 8% of its 2021 level in 2024, with the 2026 budget draft removing supply and training targets and lowering projected contraceptive coverage.
- Access now depends heavily on provincial capacity and activist networks, producing uneven availability across the country as official information campaigns falter and the sexual‑health hotline struggles to respond.